I was doing some independent research of Taurine for my specific circumstances, reviewed this long thread with many links and incorporated them into my research. Then attempted to make a general guide on taurine and came up with the following:
Taurine: A Clinical Use Guide
What the evidence actually supports, what it doesn’t, and at what dose.
Evidence key: ★★★★ multiple RCTs/meta-analysis or regulatory approval · ★★★ consistent RCT signal, limited size or duration · ★★ preliminary (single trial or biomarkers only) · ★ mechanism/animal/observational only · ✗ not supported or refuted
What it is
A sulfonic β-amino acid — not proteinogenic. Concentrated in heart, retina, skeletal muscle, leukocytes, and brain. Acts as an osmolyte, membrane and calcium stabilizer, bile-acid conjugator, scavenger of hypochlorous acid (forming taurine chloramine), and an essential modifier of mitochondrial tRNA-Leu(UUR).
Humans synthesize it from cysteine (CDO/CSAD, B6-dependent), but synthesis is modest; most intake is dietary, from meat, fish, and shellfish. Plants contain essentially none — vegans run measurably lower plasma and much lower urinary taurine [1]. Absorption via TauT/SLC6A6 is efficient (>90%); renal reabsorption exceeds 95%.
Tier 1 — Strongest evidence
MELAS ★★★★ (highest impact)
The one true disease-modifying indication. The m.3243A>G mutation causes a taurine-modification defect in mitochondrial tRNA-Leu(UUR); taurine corrects it. In a 52-week open-label phase III trial, 9 g/day (<50 kg) or 12 g/day (≥50 kg) in three divided doses completely prevented stroke-like episodes in 6 of 10 patients and significantly cut annual relapse rates, with a measurable rise in tRNA taurine modification [2]. Approved for this use in Japan. Narrow indication, large effect — the opposite of everything else on this list.
Hypertension / prehypertension ★★★★
The best-supported general-population use. Meta-analyses converge on roughly −3 to −4 mmHg systolic and −1.5 to −2.5 mmHg diastolic at 1–6 g/day [3,4]. The cleanest single trial randomized 120 prehypertensives to 1.6 g/day for 12 weeks: clinic SBP fell 7.2 mmHg vs 2.6 on placebo, with improved endothelial function and a rise in plasma H₂S that tracked the BP change [5].
Effects are larger at higher baseline BP and mechanistically distinct from ARBs and calcium blockers (H₂S signaling, TRPC3 inhibition, aquaresis), so they appear additive. Modest but real, cheap, and safe.
Heart failure (adjunct) ★★★
Old but reproducible. A double-blind crossover trial in CHF improved NYHA class, pulmonary crackles, and chest film findings vs placebo — no patient worsened on taurine, four worsened on placebo [6]. A 2024 meta-analysis of 20 RCTs (n=808) found LVEF +4.98%, NYHA −0.40, HR −3.6 bpm [4]. Small trials, mostly 3 g/day, none powered for mortality. Reasonable adjunct, not a substitute for guideline therapy.
Metabolic syndrome, lipids, insulin resistance ★★★
25 RCTs, 1,024 participants, 0.5–6 g/day: triglycerides −18.3 mg/dL, total cholesterol −8.3, LDL −6.5, plus the BP effects above [3]. In overweight/obese adults, 3 g/day improved HbA1c (−0.37%) and fasting glucose (−7.1 mg/dL); lower doses did not [7]. Fasting insulin and HOMA-IR fall consistently.
Caveat: in type 2 diabetics, 3 g/day for 8 weeks moved insulin, HOMA-IR, and endothelial adhesion markers but left fasting glucose and HbA1c unchanged [8]. Treat it as a lipid/insulin-sensitivity and vascular agent, not a glucose-lowering drug. It does not reduce body weight or BMI [9].
Tier 2 — Moderate or narrow
Inflammation & oxidative stress markers ★★★ — Meta-analysis: CRP and MDA fall significantly; TNF-α and IL-6 do not. Largest effects around 8 weeks. Heterogeneity is high, so point estimates are soft [10]. Practical corollary: taurine lowers CRP, so it can obscure an inflammatory trend you’re trying to interpret.
Cirrhosis: cramps and portal pressure ★★★ — Two of the better-designed taurine trials in medicine. A crossover RCT at ≤2 g/day cut muscle cramps by 7 per fortnight and reduced severity [11]. A separate RCT at 6 g/day for 4 weeks lowered HVPG ~12%, with 58% achieving >10% response vs 0% placebo [12].
Exercise performance and soreness ★★ — Real but small. Endurance meta-analysis g ≈ 0.40 [13]. A 2025 meta-analysis of acute single doses across 23 trials: g ≈ 0.25, best ~1 h pre-exercise, no dose-response between 1 and 6 g — a threshold effect, not a ladder [14]. Anyone selling taurine as a muscle-building or lean-mass-preserving agent in humans is ahead of the data; that work is animal-only.
Vegetarian/vegan repletion ★★ — A genuine dietary-shortfall argument rather than a pharmacologic one: vegans show lower plasma taurine (≈45 vs 58 µmol/L) and roughly one-third the urinary excretion of omnivores [1]. No trial has shown correcting this changes a clinical outcome.
First-episode psychosis ★★ — One phase 2 double-blind RCT: 4 g/day for 12 weeks alongside low-dose antipsychotics improved BPRS, depression scores, and global functioning — but not cognition [15]. Never replicated.
Tier 3 — Claimed, poorly supported
| Claim | Grade | Status |
|---|---|---|
| Slows aging / extends lifespan | ✗/★ | The 2023 Science paper extended mouse lifespan 10–12% and reported taurine falling with age [16]. Two 2025 papers dismantled the human premise: longitudinal cohorts (incl. BLSA) show circulating taurine does not decline with age and often rises, with within-person variation exceeding any age effect [17]; a second found no association with muscle mass, strength, performance, or mitochondrial function [18]. The mouse data stand; the human rationale does not. |
| Cognition, dementia, ApoE4 | ★ | In vitro/organoid work shows taurine inhibits ApoE4 aggregation, but oral taurine crosses into brain/CSF poorly and animal doses were ~1000 mg/kg. No human trial. |
| Sleep quality | ★ | Plausible via GABA-A/glycine receptors; essentially no human RCT. Glycine 3 g pre-bed has actual polysomnographic data — use that instead if sleep is the target. |
| Anxiety, depression, mood | ★ | Animal and mechanistic only. |
| NAFLD/MASLD, lowering ALT/AST | ★ | Consistent in rodents; no dedicated human RCT reporting transaminase outcomes. Human hepatic data are limited to cirrhosis and post-transplant settings. |
| Kidney protection | ★ | Review-level and preclinical. No outcome trials. |
| Tinnitus, epilepsy, retinal disease | ★ | Old, tiny, or animal studies. Retinal taurine depletion is real (vigabatrin, taurine-free formula), but that’s deficiency correction, not therapy. |
| Bone density, sarcopenia | ★ | Cell and rodent data only. |
| Hangover, “energy,” immunity | ✗ | Energy-drink effects belong to caffeine and sugar. Taurine alone is not a stimulant. |
| Weight loss | ✗ | Meta-analysis shows no effect on BMI or body weight [9]. |
Dosing & pharmacokinetics
- General adult range: 1.5–3 g/day. Most positive BP and metabolic trials sit here; 3 g/day is where glycemic and lipid effects appear most reliably [7].
- MELAS: 9–12 g/day in three divided doses with meals — a disease-specific dose, not a wellness dose [2].
- No benefit ladder above ~3 g for BP, metabolic, or performance endpoints. Exercise data show a threshold, not dose-response [14].
- Split dosing is rational: after a 4 g oral dose, peak plasma is ~1.5 h and half-life ~1 h, returning to baseline by 6–8 h [19]. Twice daily beats once daily.
- Form: plain L-taurine powder or capsules. Powder costs pennies per gram. Choose USP/NSF or Informed Choice third-party tested, single-ingredient. Food timing is irrelevant.
- Skip piperine “bioenhancers.” Taurine is already >90% absorbed, and piperine inhibits CYP3A4, P-glycoprotein, and UGT — a real interaction risk with calcium blockers, PDE5 inhibitors, statins, and many others.
- Blood taurine testing is not useful. Within-person variability swamps the signal and no validated benchmarks exist for guiding supplementation [17].
Safety
Among the better-characterized supplements. A formal risk assessment of 30 controlled trials (245 supplemented subjects) set an Observed Safe Level of 3 g/day, the highest RCT dose being 10 g/day for 6 months without significant adverse effects [20]. EFSA separately places the observed safe level at 6 g/day [21]. These two figures are frequently conflated; both are real and come from different bodies. GI upset is the main dose-dependent complaint, uncommon below 6 g.
Cautions worth naming:
- Additive hypotension. Stacked on antihypertensives, PDE5 inhibitors, or SGLT2 inhibitors, watch for orthostasis. Taurine is also aquaretic — it promoted diuresis in nonagenarians without causing hypotension or significant sodium loss, apparently by suppressing vasopressin [22].
- Leukemia niche signal. A 2025 Nature paper showed AML and blast-crisis CML stem cells import bone-marrow taurine via SLC6A6 to fuel glycolysis [23]. Entirely preclinical, marrow taurine is locally synthesized, and there is no human link between taurine intake and hematologic cancer. Reasonable to be conservative with gram-level dosing if there’s known clonal hematopoiesis or a personal history of myeloid malignancy; otherwise not actionable.
- Plaque stability. One short-term mouse study reported reduced plaque stability; it contradicts stronger prior animal work and has no human correlate. Human CV meta-analyses show benefit.
- Marker masking. Because taurine lowers CRP and is hepatoprotective, hold it during an active workup of unexplained transaminase elevation or inflammation so the trend stays interpretable.
Bottom line
Worth taking for MELAS (disease-modifying, 9–12 g/day), and as a cheap, safe adjunct for elevated blood pressure, dyslipidemia with insulin resistance, or heart failure — 1.5–3 g/day split twice daily.
Defensible as dietary replacement on a plant-based diet, and for cramps or portal hypertension in cirrhosis.
Not worth taking for longevity, sleep, cognition, weight loss, or energy.
Expect a few mmHg and a modest lipid shift, not a transformation.
References
- Laidlaw et al. Plasma and urine taurine levels in vegans. Am J Clin Nutr 1988;47:660–3.
- Ohsawa et al. J Neurol Neurosurg Psychiatry 2019;90:529–36. pubmed.ncbi.nlm.nih.gov
- Tzang et al. Nutr Diabetes 2024. Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials | Nutrition & Diabetes
- Tzang et al. Nutr J 2024. pubmed.ncbi.nlm.nih.gov
- Sun et al. Hypertension 2016;67:541–9. pubmed.ncbi.nlm.nih.gov
- Azuma et al. Clin Cardiol 1985;8:276–82. pubmed.ncbi.nlm.nih.gov
- Sun Q et al. Nutrients 2024. https://doi.org/10.3390/nu17010055
- Moludi et al. Nutr Metab 2022. Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: a randomized, clinical trial | Nutrition & Metabolism | Springer Nature Link
- Guan & Miao. Eur J Pharmacol 2020. pubmed.ncbi.nlm.nih.gov
- Faghfouri et al. Eur J Clin Nutr 2021. Profiling inflammatory and oxidative stress biomarkers following taurine supplementation: a systematic review and dose-response meta-analysis of controlled trials | European Journal of Clinical Nutrition
- Vidot et al. Aliment Pharmacol Ther 2018. https://doi.org/10.1111/apt.14950
- Schwarzer et al. Aliment Pharmacol Ther 2018. pubmed.ncbi.nlm.nih.gov
- Waldron et al. Sports Med 2018;48:1247–53. pubmed.ncbi.nlm.nih.gov
- Deng et al. Scand J Med Sci Sports 2025. pubmed.ncbi.nlm.nih.gov
- O’Donnell et al. J Clin Psychiatry 2016. pubmed.ncbi.nlm.nih.gov
- Singh et al. Science 2023. https://doi.org/10.1126/science.abn9257
- Fernandez et al. Science 2025. https://doi.org/10.1126/science.adl2116
- Marcangeli et al. Aging Cell 2025. https://doi.org/10.1111/acel.70191
- Ghandforoush-Sattari et al. J Amino Acids 2010. pubmed.ncbi.nlm.nih.gov
- Shao & Hathcock. Regul Toxicol Pharmacol 2008. pubmed.ncbi.nlm.nih.gov
- EFSA FEEDAP Panel 2012. https://www.efsa.europa.eu/en/efsajournal/pub/2736
- Miyamoto et al. J Am Geriatr Soc 2011. https://doi.org/10.1111/j.1532-5415.2010.03207.x
- Sharma et al. Nature 2025;644:263–72. pubmed.ncbi.nlm.nih.gov
Evidence current as of September 2026. Informational synthesis, not medical advice.